Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis

Nature Reviews. Neuroscience
Giles E Hardingham, Kim Q Do

Abstract

Molecular, genetic and pathological evidence suggests that deficits in GABAergic parvalbumin-positive interneurons contribute to schizophrenia pathophysiology through alterations in the brain's excitation-inhibition balance that result in impaired behaviour and cognition. Although the factors that trigger these deficits are diverse, there is increasing evidence that they converge on a common pathological hub that involves NMDA receptor hypofunction and oxidative stress. These factors have been separately linked to schizophrenia pathogenesis, but evidence now suggests that they are mechanistically interdependent and contribute to a common schizophrenia-associated pathology.

References

Oct 1, 1991·The American Journal of Psychiatry·D C Javitt, S R Zukin
Jan 1, 1989·Journal of Neural Transmission·M Carlsson, A Carlsson
Oct 13, 2000·The European Journal of Neuroscience·K Q DoM Cuénod
Oct 16, 2001·Biological Psychiatry·R SchwarczR C Roberts
Jun 5, 2002·Cellular and Molecular Neurobiology·Y GoldsmitR Pinkas-Kramarski
Aug 17, 2002·Trends in Neurosciences·Stuart A LiptonLaurie A Bankston
Mar 1, 1959·A.M.A. Archives of Neurology and Psychiatry·E D LUBYR KELLEY
Dec 2, 2004·Journal of Neuroscience Research·Ralf DringenJohannes Hirrlinger
Jun 9, 2005·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kenji HashimotoMasaomi Iyo
Sep 27, 2006·American Journal of Obstetrics and Gynecology·Ron BelooseskyMichael G Ross
Aug 7, 2007·Proceedings of the National Academy of Sciences of the United States of America·Takatoshi HikidaAkira Sawa
Oct 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·René GysinKim Q Do
Nov 16, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Suzie LavoieKim Q Do
Mar 18, 2008·Nature Neuroscience·Sofia PapadiaGiles E Hardingham
Jun 2, 2009·Current Opinion in Neurobiology·Kim Q DoMichel Cuenod
Jun 30, 2009·Biological Psychiatry·Stefania SchiavoneKarl-Heinz Krause
Sep 1, 2009·Behavioural Brain Research·Daisuke IbiKiyofumi Yamada
Nov 6, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Eva K WirthUlrich Schweizer
Jan 21, 2010·Nature Reviews. Neuroscience·Peter J Uhlhaas, Wolf Singer
Feb 5, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Karthik BodhinathanThomas C Foster
Feb 19, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Pascal SteulletKim Q Do
Jul 17, 2010·The International Journal of Neuropsychopharmacology·Jeremy W GawrylukL Trevor Young
Aug 3, 2010·Antioxidants & Redox Signaling·Daniel Martins-de-SouzaSabine Bahn
Aug 18, 2010·Antioxidants & Redox Signaling·Daisuke Matsuzawa, Kenji Hashimoto
Sep 16, 2010·Nature Reviews. Neuroscience·Giles E Hardingham, Hilmar Bading
Sep 28, 2010·Antioxidants & Redox Signaling·Karen F S Bell, Giles E Hardingham
Oct 20, 2010·Progress in Neurobiology·Alan S Brown
Oct 28, 2010·Antioxidants & Redox Signaling·Giles E Hardingham, Stuart A Lipton

❮ Previous
Next ❯

Citations

Jul 2, 2016·Free Radical Biology & Medicine·Paul S Baxter, Giles E Hardingham
Jul 30, 2016·Frontiers in Neuroscience·Kati KoidoEero Vasar
Aug 17, 2016·Oxidative Medicine and Cellular Longevity·Kärt KriisaMihkel Zilmer
Mar 18, 2017·International Journal of Molecular Sciences·Henry BarronRomina Mizrahi
Jun 1, 2017·NPJ Schizophrenia·Kazu NakazawaKazuhito Nakao
Feb 13, 2017·Schizophrenia Research·Eveline GeiserMicah M Murray
Feb 12, 2017·Trends in Neurosciences·Huan-Xiang Zhou, Lonnie P Wollmuth
Sep 15, 2016·Journal of Psychopharmacology·Gavin P Reynolds, Joanna C Neill
Oct 14, 2017·Cerebral Cortex·Ramon PlaJohn L R Rubenstein
May 23, 2018·Medicinal Research Reviews·Xu-Feng Huang, Xueqin Song
Sep 12, 2017·The Australian and New Zealand Journal of Psychiatry·Yiru ZhangCynthia Shannon Weickert
May 12, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sina HafiziRomina Mizrahi
Jun 29, 2018·Food & Function·Torsten BohnRalph Rühl
Feb 2, 2018·Journal of Neural Transmission·Manuela Mellone, Fabrizio Gardoni
Dec 27, 2018·Antioxidants & Redox Signaling·Yeni KimRenata Santos
Jun 6, 2019·SLAS Technology·Aleksei V YantsevichSergey A Usanov
Jul 10, 2019·The International Journal of Neuropsychopharmacology·Emeline MullierPatric Hagmann
Jan 25, 2020·Journal of Neurochemistry·Marta VieiraVictor Anggono
Oct 19, 2019·Translational Psychiatry·Fedor E GusevEvgeny I Rogaev
May 7, 2020·Current Pharmaceutical Design·Giulia LisiCinzia Niolu
May 17, 2017·The Journal of General Physiology·Johansen B AminLonnie P Wollmuth
Jun 24, 2018·Molecular Psychiatry·Jyothika KumarPeter F Liddle
Jun 14, 2019·Frontiers in Molecular Neuroscience·Carolina RozaJavier Márquez
Sep 14, 2019·Brain and Behavior·Tatyana M MatveevaJonathan C Gewirtz
Dec 19, 2019·Frontiers in Genetics·Elizaveta S ErshovaSvetlana V Kostyuk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Addison Disease

Addison's disease, also known as primary adrenal insufficiency and hypocortisolism, is a long-term endocrine disorder in which the adrenal glands do not produce enough steroid hormones. Discover the latest research on Addison's disease here.

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis is a form of of brain inflammation due to antibodies against NMDA receptors. Discover the latest research on anti-NMDA receptor encephalitis here.